Open Calls for Proposals

Pioneer Award

Encourage and support innovative basic and/or clinical scientific research in the area of Inflammatory Bowel Diseases (IBD) across Europe.

Funding: 300K EUR for 2 years

Global Grant

Extend the outreach and global perspective of IBD research and may focus on aspects of IBD pathogenesis (e.g. environmental impact, genetics), epidemiology and/or clinical care, among others. Applications must be multicenter and address knowledge gaps and/or unmet needs relevant to low and lower-middle income countries and feature strong contributions from these countries. At least one Principal Investigator who is from a low- or lower-middle income country.

Funding: 300K EUR for 2 years

https://www.ecco-ibd.eu/science/fellowships-and-grants.html

(another deadline on 3.10)
The Program supports investigator-initiated studies (IIS) and education projects on molecular profiling in oncology, with the goal to increase high quality molecular profiling and help democratize the future of precision medicine.
Funding: Up to $200,000 over one year.
www.thermofisher.com/il/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/clinical-research-grant-program.html
https://assets.thermofisher.com/TFS-Assets/CSD/Reference-Materials/Oncomine-Grant-Rules-2025.pdf

Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research.
Projects that hold a prospect for transformative breakthroughs that prevent, treat or cure type 1 diabetes will be given
top priority.
Funding: will be reviewed on a per-application basis.
https://www.breakthrought1d.org/explore-research/funding-opportunities/
https://www.breakthrought1d.org/explore-research/research-strategy/

To provide catalytic funding for exploratory research projects within the thematic research areas pathogenic fungi, novel antimicrobial resistance (AMR) tools, and harnessing innate immunity.
Main applicant must be anchored in Denmark. International collaboration is encouraged.
Funding: 6.5M DDK (~954K USD) for up to 3 years
https://novonordiskfonden.dk/en/grant/infectious-diseases-catalyst-grants-2025/

Honoring those who’ve dedicated their careers to furthering the field of Neuroscience.
Outstanding Career and Research Achievements Awards, Early Career Awards, Honoring Support For Women, Science Education and Outreach Awards.
For the full list of Award and Prizes: https://www.sfn.org/initiatives/awards#lifetime

This RFP supports innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug development programs for frontotemporal dementia (FTD).

Funding: Up to $350,000 over one year.

LEARN MORE

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Fund creative, innovative research into non-drug approaches that will play a vital part in helping people living with Parkinson’s manage their daily challenges and take control of life with Parkinson’s. These may include:
– Speech and language, physiotherapy and occupational therapies
– Approaches to managing mental health
– Lifestyle changes including exercise, dance and nutrition
– Aids and devices
– Complementary therapies
Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
Funding: up to £200K for up to 24 months
https://www.parkinsons.org.uk/research/grants-non-drug-approaches

Research Grant
Research grants are intended to encourage the development of new information that contributes to the understanding of the basic etiology and
pathogenesis of cystic fibrosis.
Funding: $150 per year for up to 3 years
https://www.cff.org/researchers/research-grants
Path to a Cure (PTAC) Research Grant
To facilitate or enable the development of new information that may contribute to the development of new therapies focused upon
repair or replacement of CFTR variants not served by existing small molecule modulators.
* Applicants seeking to submit proposals focused on topics such as mucociliary clearance and airway hydration, infection and inflammation,
or non-lung manifestations of disease should apply through the Research Grant mechanism.
Funding: $150 per year for up to 3 years
https://www.cff.org/researchers/path-cure-academic-programs

Pilot and Feasibility Awards
For developing and testing new hypotheses and/or methods, and supporting promising new investigators as they establish themselves in research
areas relevant to cystic fibrosis.
Funding: $50 per year for up to 2 years
https://www.cff.org/researchers/pilot-and-feasibility-awards
Path to a Cure (PTAC) Pilot and Feasibility Award
Intended to support projects that will develop and test new hypotheses and/or new methods that could eventually contribute to
the development of a cure for Cystic Fibrosis (CF) and to support promising new investigators as they establish themselves in research areas relevant
to cystic fibrosis.
*Applicants seeking to submit proposals focused on topics such as mucociliary clearance and airway hydration, infection and inflammation,
or non-lung manifestations of disease should apply through the Pilot and Feasibility Award mechanism.
Funding: $50 per year for up to 2 years
https://www.cff.org/researchers/path-cure-academic-programs

Support large-scale research projects concerning metastatic, lethal prostate cancer. PCF seeks high-risk, currently unfunded projects.
Research proposals in the following topic areas are solicited:
• Theranostics.
• Drugging currently undruggable oncology targets: preventing progression to lethal disease.
• Improved biotechnologies for precision medicine.
• First-in-field immunotherapies for prostate cancer.
• Artificial intelligence/machine learning to better inform patient outcomes.
• Host microbiome and tumor metabolism
Teams of at least 5 investigators from minimum 4 non-profit academic research institutions, Including 2 young investigators as integral
contributors. Cross-disciplinary teams that are diverse and inclusive will be favored.
Funding: $5 – $10M per award over 3–5 years
https://www.pcf.org/science-impact/for-researchers/open-rfas/
https://www.trdf.co.il/files/2025-TACTICAL-Award-RFA_4-8-25.pdf
https://www.trdf.co.il/files/LOI_Form_2025-TACTICAL_Awards.pdf

Wong Family Foundation Research Award
Research Award may include (but are not limited to):
Basic research in mechanisms relating to intractability, e.g., multi-drug resistant epilepsy
Model development (especially for infantile spasms or intractable epilepsy)
New technologies related to epilepsy (imaging, electrophysiology, etc.)
Research grants
Research grant proposals should address one of the following four high-priority areas:
Understanding phenotypic heterogeneity in TSC, i.e., research on genetic, biologic, or environmental factors that might explain why TSC is so different from person to person
Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
Improving TSC disease models, whether cell-based, tissue-based, or animal models
Developing clinical biomarkers or patient-reported outcome measures for TSC, particularly those that assess disease burden or stratify an individual’s risk of progression or developing specific manifestations of TSC
For early-career researchers. Fully supports collaborative projects between co-investigators.
Funding: $75K per year for 2 years
https://www.tscalliance.org/researchers/grants-funding/
The TSC Biosample Repository houses human biological materials such as blood, DNA, and tissues linked to detailed clinical data.
To request samples: https://www.tscalliance.org/research-strategy/biosample-repository/

Seeks to identify collaborators who have analytically validated biomarker assays to deploy in existing PPMI bio samples to enhance the biological definition of Parkinson’s disease (PD) and related disorders, both before and after symptom onset.
Funding: Up to $750K for 6 to 24 months
https://www.michaeljfox.org/grant/ppmi-biofluid-biomarkers-program

With efforts to improve technology and affordability, mAb costs have decreased significantly in the last 30 years and have stagnated at around $50-100 per gram. In order to improve mAb affordability in low- and middle-income countries, we will need to reach a final drug substance cost-of-goods of $10 per gram.
Proposals are solicited to develop proof-of-concept for manufacturing platforms that produce monoclonal antibodies at a final drug substance cost-of-goods of $10/gram (Option A (application by 31.1.25)). The goal is to catalyze and accelerate multiple, diverse, innovative bioprocessing approaches that hold the promise of low cost-of-goods mAbs.
Additionally, Gates Foundation is interested in hearing from organizations that have already completed proof-of-concept work that could result in cost-of-goods of $10/gram and may be interested in additional support (Option B (application by 31.5.25)).
Objectives of the challenge (both Option A and Option B):  Advance innovative and bold ideas that enhance production efficiency and improve overall process economics for mAb production, resulting in a final drug substance cost-of-goods of $10/gram. This includes, but is not limited to:
* Alternative hosts to mammalian cell culture
* Alternative to standard downstream purification methods
* Reduction in material costs
* Push the boundaries of current technology by harnessing disruptive innovations, possibly from parallel industries, and identify process improvements to reduce manufacturing costs
* Rethink existing methods of working such as release testing process and costs, high-quality and affordable raw materials and critical reagents
Funding: Option A: up to $750K for up to 18 months.  Option B: Potential funding and grant terms will be evaluated on a per-project basis.
https://gcgh.grandchallenges.org/challenge/innovations-exceptionally-low-cost-monoclonal-antibody-mab-manufacturing

A new flagship program to actively promote translational and clinical research.
Funding: 200K Swiss francs (~$232K)
https://osteology.org/en/research/funding-opportunities/applied-research-grants/

To encourage the development of novel approaches to address bladder cancer. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to bladder cancer research.
Funding: $50K for 1 year (No overhead)
https://www.aacr.org/grants/aacr-grant-for-innovative-bladder-cancer-research/

Pilot Clinical Trial Award:

Applications must address one focus area: • Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. • Clinical Care: Improving aspects of clinical care and symptom management for ALS.

Funding: up to $2M for 3 years

Clinical Outcomes and Biomarkers Award: Supports the development and/or validation of clinical outcomes and/or biomarkers to enrich clinical trials in ALS.

Funding: up to $750K for 3 years

Therapeutic Development Award: Supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration Investigational New Drug (IND)- enabling studies

Funding: up to $1.5M for 3 year

Therapeutic Idea Award:

Supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

Funding: to $600K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663102

Catalyst Award

Prioritizes projects that advance research to clinical trial readiness. This includes the development of biomarkers and optimization of promising new entities with established proof-of-concept to improve pharmacokinetics/pharmacodynamics, safety profiles, and/or formulations to advance these new entities further in development.

Funding: max of $120K for 1 year (No Overhead)

https://www.trdf.co.il/files/CATALYST AWARD.pdf

Rare Epilepsy Partnership Award

An overarching goal of this funding mechanism is to develop resources and data that will be made available to the research community to accelerate research on rare epilepsies.

Funding: max of $100K for 1 year (No Overhead)

https://www.trdf.co.il/files/REPA-Guidelines_Final.pdf

Transforming Diagnosis Award:

Supports research seeking to transform diagnosis and prognosis to better determine the trajectory, long-term outcomes, and impact of AD/ADRD following military service and/or TBI.

Funding: up to $1.7M for 4 years

Transforming Research Award: Supports transformative research studies that reduce risk of or prevent the development of AD/ADRD with near-term, high-impact outcomes and demonstrate significant positive impact toward improving patient care and/or quality of life. Risk reduction considering TBI is of particular interest

Funding: up to $1M for 3 years

Transforming Care Award: Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both that clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not include medical care (such as medical interventions administered by a physician)

Funding: up to $31.8M for 4 year

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663104

Investigator-Initiated Research Award:

Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care

Funding: up to $1.4M for 4 years

Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award:

Supports the addition of new early-career investigators (ECIs) to the unique, interactive virtual Clinical Trial Academy that provide intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.4M for 4 years

Pilot Award:

Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.

Funding: up to $350K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663103

Breakthrough Award Level 1 and 2 (LOI):

Supports promising research with high potential to lead to or make breakthroughs in breast cancer.

Funding: up to $2.4M for 4 years

Breakthrough Award Level 3 (Pre-proposal):

Supports promising research with high potential to lead to or make breakthroughs in breast cancer.

Funding: up to $5M for 4 years

Clinical Research Extension Award (LOI):

Supports the extension or expansion of data collection, followup, and analysis of breast cancer clinical studies.

Funding: up to $5M for 4 years

Era of Hope Scholar Award (LOI):

Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.

Funding: to $3.5M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101

(more deadlines on Sep 15, Nov 15)

Supporting breakthroughs in life science research areas, including but not limited to those indicated below. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

These challenges represent the most urgent, complex problems in cancer research – problems that can only be solved through collaboration across borders and disciplines:

• AI-human collaborations in cancer
• Cancer avoidance
• The dark proteome
• Mechanisms driving mutational signatures
• The nervous system and cancer
• Rewiring cancer cells
• TME dynamics

Shortlisted teams are notified and given seed funding to support submission of a full application.
Funding: awards of up to £20m ($25m).

New challenges | Cancer Grand Challenges

Applications | Cancer Grand Challenges

To early-career scientists advancing human immunology, vaccine discovery, and immunotherapy for major global diseases.
Researchers across scientific disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, and nanotechnology are encouraged to apply.
Funding: $150K for 1 year (No overhead)
https://www.michelsonmedicalresearch.org/michelson-prizes-next-generation

To promote and support early-career investigators* who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field.
The Inovitro® system (which will provided by Novocure, if needed), must be included in the experimental design.
* Received first faculty position with the title of assistant professor or the equivalent within the past 6 years (before December 1, 2025).
Funding: $300K for 3 years
https://www.aacr.org/grants/aacr-novocure-career-development-award-for-cancer-research-aacr-grants/

Funds an established, leading PIs pursue a potentially ground-breaking, high-risk project in basic research in ALS.
Funding: 200K CHF (~880,000 NIS) for 2 years (one or two grants will be funded).
https://www.radala-foundation.com/index.html

For 2025, the HMRC has identified relevant areas of research in the field of anti-doping; in particular, those related to the 2024 List of Prohibited Substances and Methods.

It should be noted that higher priority will be granted to proposals addressing:

 Detection/improvement of detection/quantification of peptide and protein hormones and growth factors, preferably by, but not limited to, chromatography-mass spectrometric methods;

 Improved window (retrospectivity) of detection of prohibited substances/methods (e.g., detection of new longterm metabolites including administration studies, improved methodologies of detection, analyte multiplexing);

 Pharmacokinetic studies to establish thresholds or minimum reporting levels of prohibited substances or their metabolites (e.g., beta-2 agonists, stimulants) to distinguish permitted (e.g., out-of-competition or route) from prohibited use, natural sources vs. intended use or presence in food residues;

 Detection of autologous blood transfusion, including validation of candidate biomarkers or molecular/cellular/subcellular signatures;

 The Athlete Biological Passport (e.g., new biomarkers of doping or confounding factors relevant to the hematological, steroidal or endocrine [markers of growth hormone] modules); and

 Selected Certified Reference Material synthesis (please consult WADA for materials needed).

Funding: not mentioned. No overhead.

https://www.wada-ama.org/en/news/wada-launches-call-proposals-2025-scientific-research-grants

The purpose of the Fund is to provide grants for clinical, hypothesis-driven research that offers substantial promise for meaningful advances in the prevention, diagnosis and treatment of children’s diseases, particularly research that offers broad-based applications.

Funding: up to $550K for 3 years.

www.thrasherresearch.org

(Additional deadline on 1.11)

Funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.

Funding: typically awards grants in the $50K-$300K range for 1-3 years, but there is no minimum or maximum funding level restriction (No Overhead)

https://sens.org/our-research/submit-a-grant-proposal/

To help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to generate the essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.
Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
Funding: up to £150K for 12 to 18 months, for projects involving in vivo work, an award amount of up to £200K will be considered.
https://www.parkinsons.org.uk/research/drug-accelerator-awards
Drug accelerator award workshop for applicants will be held on Jul 3, 4PM, for registration:
https://parkinsons-org-uk.zoom.us/meeting/register/

Support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer.

Funding: $3M over 3 years (Non profit)

https://themarkfoundation.org/endeavor/

Accepts applications in all areas of research relevant to PWS, but we are particularly interested in Supporting projects that will lead to new interventions to alleviate the symptoms associated with PWS.
Funding: up to $150K for 18 months
https://www.fpwr.org/grant-program

With the Research Grants in open competition program, the LEO Foundation aims to support the best dermatology research projects worldwide, within basic, translational, technical, epidemiological, or clinical research. We welcome applications for research projects that improve the understanding of skin biology, as well as the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms. We also welcome applications that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life, and the societal costs involved.

Funding:  up to 4 Million DKK (~$560K) for 1-3 years.

https://leo-foundation.org/en/grants-and-awards

https://leo-foundation.org/en/grants-and-awards/research-grants

(another deadline on Nov 15)

Supporting breakthroughs in life science research areas, including but not limited to those indicated below. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

To support high quality research on non-pharmacological treatment of symptoms experienced by patients with Parkinson’s disease and other movement disorders performed in a research center in or related to Switzerland.
The funding period is two years, with a possible extension up to a maximum of 4 years. It includes any support of the research project, with the exception of the applicant’s own salary.
https://www.jggf.ch/en/neurology-research

For UK institutions to invite an eminent senior professor from overseas, to bring genuinely novel expertise and enhance the skills and knowledge of academic staff and students in an underrepresented area in the UK. Priority will be given to new or recent collaborations and visits with a variety of activities beyond research. Applications will be considered in all subject areas except:
• studies of disease, illness and disabilities in humans and animals
• research that is intended to inform clinical practice or the development of medical applications
Funding: Applications are invited for £10K – £150K. Duration: 3-12 months. Grants between 3 and 6 months must be completed in one visit. Grants between 6 and 12 months can be spread over two or more visits.
https://www.leverhulme.ac.uk/schemes-at-a-glance

The Program supports investigator-initiated studies (IIS) and education projects on molecular profiling in oncology, with the goal to increase high quality molecular profiling and help democratize the future of precision medicine.
Funding: Up to $200,000 over one year.
www.thermofisher.com/il/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/clinical-research-grant-program.html
https://assets.thermofisher.com/TFS-Assets/CSD/Reference-Materials/Oncomine-Grant-Rules-2025.pdf

IMRF provides research funding in the fight against connective tissue diseases, including, but not limited to emphysema and genetic diseases, especially those related to elastin and elastase concentrating in the causes as opposed to the cure or treatment of the disease. Research may also include the fields of immunology and bio-chemistry.
Funding: Up to $100K over 1-3 years (No Overhead).
https://www.mandlresearch.org/apply-1

Funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.

Funding: typically awards grants in the $50K-$300K range for 1-3 years, but there is no minimum or maximum funding level restriction (No Overhead)

https://sens.org/our-research/submit-a-grant-proposal/

Supporting breakthroughs in life science research areas. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

Research to characterise misophonia, including exploring its underlying mechanisms, expression, natural history, or development through interdisciplinary characterisation.

• Development of diagnostic tools to facilitate rapid, physiologically-relevant assessment.
• Clinical and/or model studies of specific interventions, including studies investigating comparative effectiveness, novel treatments, and controlled trials of promising treatments.

Funding: up to $200,000/year up to two years. Non-profit.

https://misophoniaresearchfund.org/scientific-funding/

Metagenomic Next Generation Sequencing to Detect, Identify and Characterize Pathogens

Through this Grand Challenge, funding will be offered to 10 scientific groups to explore the identification, characterisation and context of infectious disease in low and middle-income country (LMIC) settings. Selected applicants will benefit from onsite next generation sequencing and rapid pathogen detection to better understand their local pathogen landscape.

Funding: up to $200,000 over 2 years.

https://gcgh.grandchallenges.org/challenge/metagenomic-next-generation-sequencing-detect-identify-and-characterize-pathogens

 (Abstracts may be submitted at any time until the closing date)

AOI #20 DRIVe Forward

Aims to develop products, capabilities, and technologies to detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute MCMs rapidly and agnostically.

Especially interested in proposals that aim to address one or more of the following topics:

1. Microbiome-based therapies
2. Resilience to infection
3. Next-generation vaccines
4. Next-generation therapeutic antibodies
5. Artificial blood products
6. Extremely mobile viral diagnostic platforms for use in extremely remote settings
7. Non-pharmacological approaches for enhanced immunity

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

(Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date)

Research Areas of Interest (please see BAA for more details)

1. Damage Control Resuscitation
2. Prolonged Field Care (PFC)
3. Portable Lab Assays and Diagnostics
4. Force Health Protection and Environmental Medicine
5. Brain Health
6. Immune Response
7. Chronic Pain
8. Automation of Systematic Reviews and Metanalysis
9. Medical Simulation and Training Technologies
10. Human Performance Optimization
11. Canine Medicine and Performance

Most projects are anticipated to have a total cost at or below $1,500,000 (including indirect costs). Projects that have a total cost higher than $1,500,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $5,000,000.00 (including Indirect costs).

Duration: up to 5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=549113